NCE-1 Intelligence & Market Opportunity

Ogsiveo

Nirogacestat

Anticancer

Tablet

Ogsiveo is an oral therapy for adults with desmoid tumors that are actively progressing. It targets a protein involved in tumor formation, helping reduce tumor size and manage symptoms.

Approval Date

27-Nov-23

NCE-1 Date

27-Nov-27

NCE Date

27-Nov-28

Commercial snapshot

Market performance & projections

Revenue ($M)

262

CAGR (%)

0.283

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

355

2027

475

2028

590

2029

710

2030

845

2031

914

2032

933

Molecule profile

Details & specifications

Molecule

Nirogacestat

Innovator

SPRINGWORKS THERAPEUTICS INC

Dosage Form

Tablet

Strength

50 mg

Therapeutic Category

Anticancer

Usage

To treat adults with progressing desmoid tumors who require systemic treatment

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.